vs
ARTIVION, INC.（AORT）とBRC Group Holdings, Inc.（RILY）の財務データ比較。上の社名をクリックして会社を切り替えられます
BRC Group Holdings, Inc.の直近四半期売上が大きい（$188.3M vs $116.0M、ARTIVION, INC.の約1.6倍）。BRC Group Holdings, Inc.の純利益率が高く（47.9% vs 2.1%、差は45.9%）。ARTIVION, INC.の前年同期比売上増加率が高い（19.2% vs -21.9%）。過去8四半期でARTIVION, INC.の売上複合成長率が高い（9.1% vs -15.4%）
Artivion, Inc.は心血管移植向けの極低温保存した人体組織の流通、及び医療機器の開発を行う医療企業です。同社の製品には、余分な細胞物質と抗原を除去する処理を施した人間の心臓弁、手術用接着剤BioGlueなどがあり、臨床現場のニーズに応えています。
AORT vs RILY — 直接比較
売上が大きい
RILY
1.6倍大きい
$116.0M
売上成長率が高い
AORT
+41.1%の差
-21.9%
純利益率が高い
RILY
純利益率が45.9%高い
2.1%
2年売上CAGRが高い
AORT
2年複合成長率
-15.4%
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $116.0M | $188.3M |
| 純利益 | $2.4M | $90.3M |
| 粗利率 | 63.1% | 79.5% |
| 営業利益率 | 9.2% | 32.3% |
| 純利益率 | 2.1% | 47.9% |
| 売上前年比 | 19.2% | -21.9% |
| 純利益前年比 | 114.7% | 1710.8% |
| EPS（希薄化後） | $0.06 | $2.78 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
売上AORTRILY
| Q4 25 | $116.0M | $188.3M | ||
| Q3 25 | $113.4M | $215.3M | ||
| Q2 25 | $113.0M | $188.2M | ||
| Q1 25 | $99.0M | $197.2M | ||
| Q4 24 | $97.3M | $241.0M | ||
| Q3 24 | $95.8M | $225.5M | ||
| Q2 24 | $98.0M | $256.0M | ||
| Q1 24 | $97.4M | $263.4M |
純利益AORTRILY
| Q4 25 | $2.4M | $90.3M | ||
| Q3 25 | $6.5M | $91.1M | ||
| Q2 25 | $1.3M | $139.5M | ||
| Q1 25 | $-505.0K | $-10.0M | ||
| Q4 24 | $-16.5M | $-5.6M | ||
| Q3 24 | $-2.3M | $-284.4M | ||
| Q2 24 | $-2.1M | $-433.6M | ||
| Q1 24 | $7.5M | $-49.2M |
粗利率AORTRILY
| Q4 25 | 63.1% | 79.5% | ||
| Q3 25 | 65.6% | 83.7% | ||
| Q2 25 | 64.7% | 81.3% | ||
| Q1 25 | 64.2% | 81.4% | ||
| Q4 24 | 63.2% | 79.8% | ||
| Q3 24 | 63.7% | 82.1% | ||
| Q2 24 | 64.6% | 84.5% | ||
| Q1 24 | 64.6% | 85.3% |
営業利益率AORTRILY
| Q4 25 | 9.2% | 32.3% | ||
| Q3 25 | 11.1% | 30.4% | ||
| Q2 25 | 7.4% | 5.7% | ||
| Q1 25 | 2.2% | -31.2% | ||
| Q4 24 | 2.7% | -69.2% | ||
| Q3 24 | 4.6% | -36.4% | ||
| Q2 24 | 6.6% | -90.8% | ||
| Q1 24 | 26.0% | -6.1% |
純利益率AORTRILY
| Q4 25 | 2.1% | 47.9% | ||
| Q3 25 | 5.7% | 42.3% | ||
| Q2 25 | 1.2% | 74.1% | ||
| Q1 25 | -0.5% | -5.1% | ||
| Q4 24 | -16.9% | -2.3% | ||
| Q3 24 | -2.4% | -126.1% | ||
| Q2 24 | -2.2% | -169.4% | ||
| Q1 24 | 7.7% | -18.7% |
EPS（希薄化後）AORTRILY
| Q4 25 | $0.06 | $2.78 | ||
| Q3 25 | $0.13 | $2.91 | ||
| Q2 25 | $0.03 | $4.50 | ||
| Q1 25 | $-0.01 | $-0.39 | ||
| Q4 24 | $-0.40 | $-0.01 | ||
| Q3 24 | $-0.05 | $-9.39 | ||
| Q2 24 | $-0.05 | $-14.35 | ||
| Q1 24 | $0.18 | $-1.71 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $64.9M | $226.6M |
| 総負債低いほど良い | $215.1M | $1.4B |
| 株主資本純資産 | $448.2M | $-171.5M |
| 総資産 | $884.8M | $1.7B |
| 負債/資本比率低いほどレバレッジが低い | 0.48× | — |
8四半期トレンド — 暦四半期で整列
現金・短期投資AORTRILY
| Q4 25 | $64.9M | $226.6M | ||
| Q3 25 | $73.4M | $184.2M | ||
| Q2 25 | $53.5M | $267.4M | ||
| Q1 25 | $37.7M | $138.3M | ||
| Q4 24 | $53.5M | $146.9M | ||
| Q3 24 | $56.2M | $159.2M | ||
| Q2 24 | $55.0M | $236.9M | ||
| Q1 24 | $51.1M | $190.7M |
総負債AORTRILY
| Q4 25 | $215.1M | $1.4B | ||
| Q3 25 | $214.9M | $1.3B | ||
| Q2 25 | $215.6M | $1.3B | ||
| Q1 25 | $314.7M | $1.4B | ||
| Q4 24 | $314.3M | $1.5B | ||
| Q3 24 | $314.0M | — | ||
| Q2 24 | $313.6M | — | ||
| Q1 24 | $313.3M | — |
株主資本AORTRILY
| Q4 25 | $448.2M | $-171.5M | ||
| Q3 25 | $438.7M | $-260.5M | ||
| Q2 25 | $419.9M | $-351.7M | ||
| Q1 25 | $294.3M | $-496.8M | ||
| Q4 24 | $276.2M | $-488.2M | ||
| Q3 24 | $304.7M | $-497.6M | ||
| Q2 24 | $295.1M | $-218.3M | ||
| Q1 24 | $295.0M | $228.4M |
総資産AORTRILY
| Q4 25 | $884.8M | $1.7B | ||
| Q3 25 | $857.7M | $1.7B | ||
| Q2 25 | $838.4M | $1.5B | ||
| Q1 25 | $791.2M | $1.5B | ||
| Q4 24 | $789.1M | $1.8B | ||
| Q3 24 | $803.1M | $2.2B | ||
| Q2 24 | $789.5M | $3.2B | ||
| Q1 24 | $784.0M | $5.0B |
負債/資本比率AORTRILY
| Q4 25 | 0.48× | — | ||
| Q3 25 | 0.49× | — | ||
| Q2 25 | 0.51× | — | ||
| Q1 25 | 1.07× | — | ||
| Q4 24 | 1.14× | — | ||
| Q3 24 | 1.03× | — | ||
| Q2 24 | 1.06× | — | ||
| Q1 24 | 1.06× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $19.6M | $26.2M |
| フリーキャッシュフロー営業CF - 設備投資 | $-7.9M | — |
| FCFマージンFCF / 売上 | -6.9% | — |
| 設備投資強度設備投資 / 売上 | 23.7% | — |
| キャッシュ転換率営業CF / 純利益 | 8.06× | 0.29× |
| 直近12ヶ月FCF直近4四半期 | $839.0K | — |
8四半期トレンド — 暦四半期で整列
営業キャッシュフローAORTRILY
| Q4 25 | $19.6M | $26.2M | ||
| Q3 25 | $22.3M | $-60.6M | ||
| Q2 25 | $15.0M | $-25.6M | ||
| Q1 25 | $-17.0M | $184.0K | ||
| Q4 24 | $10.1M | $-2.7M | ||
| Q3 24 | $11.5M | $19.5M | ||
| Q2 24 | $6.1M | $111.5M | ||
| Q1 24 | $-5.5M | $135.4M |
フリーキャッシュフローAORTRILY
| Q4 25 | $-7.9M | — | ||
| Q3 25 | $17.7M | — | ||
| Q2 25 | $11.7M | — | ||
| Q1 25 | $-20.6M | — | ||
| Q4 24 | $8.7M | — | ||
| Q3 24 | $7.8M | — | ||
| Q2 24 | $3.6M | — | ||
| Q1 24 | $-9.1M | — |
FCFマージンAORTRILY
| Q4 25 | -6.9% | — | ||
| Q3 25 | 15.6% | — | ||
| Q2 25 | 10.4% | — | ||
| Q1 25 | -20.8% | — | ||
| Q4 24 | 9.0% | — | ||
| Q3 24 | 8.2% | — | ||
| Q2 24 | 3.7% | — | ||
| Q1 24 | -9.3% | — |
設備投資強度AORTRILY
| Q4 25 | 23.7% | — | ||
| Q3 25 | 4.1% | — | ||
| Q2 25 | 2.9% | — | ||
| Q1 25 | 3.7% | — | ||
| Q4 24 | 1.5% | — | ||
| Q3 24 | 3.8% | — | ||
| Q2 24 | 2.6% | — | ||
| Q1 24 | 3.7% | — |
キャッシュ転換率AORTRILY
| Q4 25 | 8.06× | 0.29× | ||
| Q3 25 | 3.42× | -0.66× | ||
| Q2 25 | 11.16× | -0.18× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -0.73× | — |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
AORT
| Aortic Stent Grafts | $43.3M | 37% |
| On X | $27.8M | 24% |
| Preservation Services | $24.1M | 21% |
| Surgical Sealants | $20.3M | 18% |
| Other Products | $463.0K | 0% |
RILY
| Transferred At Point In Time | $101.4M | 54% |
| Wealth Management Segment | $30.7M | 16% |
| Corporate Finance Consulting And Investment Banking Fees | $27.1M | 14% |
| Services And Fees | $24.8M | 13% |
| Commissions Fees And Reimbursed Expenses | $4.8M | 3% |
